The world leader in addiction treatment with 20 years of experience and a unique, patient-focused approach. We didn’t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They’re often unaware of their treatment options, have limited access to treatment, or simply don’t seek it out because they’re afraid of being stigmatized. Since our inception, we have actively partnered with healthcare professionals, the public health community, policymakers, and payers to humanize people suffering from addiction and to treat addiction as a chronic, relapsing medical condition rather than a social disorder. We believe that people with addiction should be treated as patients, just like sufferers other chronic diseases. The past two decades have been marked by strong growth and an expansion into more than 40 countries. While opioid dependence marketplace has seen much innovation, we at Indivior are building on our intimate understanding of the patient journey to further advance opioid dependence treatment and combat broader addiction epidemics including opiate overdose, alcohol use disorders, cocaine intoxication and schizophrenia by bringing to market novel treatment solutions worldwide.
Company Growth (employees)
Slough, GB
Size (employees)
831 (est)
Indivior is headquartered in Slough, GB

Indivior Office Locations

Indivior has offices in Slough, Richmond, Ottawa, Mannheim and in 11 other locations
Slough, GB (HQ)
105 Bath Rd
Beijing, CN
1 Dong San Huan Zhong Lu
Massy, FR
15 Rue Ampère
Milano, IT
7 Via Giovanni Spadolini
Mannheim, DE
3 Hermsheimer Str.
Ottawa, CA
2 Gurdwara Rd
Show all (15)

Indivior Data and Metrics

Indivior Financial Metrics

Indivior's revenue was reported to be £819.4 m in FY, 2016 which is a 18% increase from the previous period.

Revenue (FY, 2016)

819.4 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

736.5 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

27.1 m

Market capitalization (24-Jul-2017)

2.3 b

Closing share price (24-Jul-2017)


Cash (31-Dec-2016)

535.9 m
Indivior's current market capitalization is £2.3 b.
GBPFY, 2013FY, 2014FY, 2015FY, 2016


799.6 m762.9 m693.8 m819.4 m

Revenue growth, %


Cost of goods sold

68.4 m65 m66.4 m82.9 m

Gross profit

731.2 m697.9 m627.4 m736.5 m

Gross profit Margin, %


Operating expense total

274.2 m313.4 m390.7 m621.1 m

Pre tax profit

457 m383.8 m195 m75.9 m

Net Income

321.6 m275.7 m156 m27.1 m
GBPFY, 2013FY, 2014FY, 2015FY, 2016


4.6 m226.5 m361.7 m535.9 m

Accounts Receivable

111.1 m110.8 m130.9 m158.8 m

Current Assets

149.9 m386.6 m558.4 m766.7 m


121.7 m62.3 m119.3 m105.3 m


8.5 m62.3 m48 m64.3 m

Total Assets

280.1 m511.1 m725.7 m936.3 m

Accounts Payable

35.5 m19.8 m20.9 m25.6 m

Current Liabilities

296.6 m316.1 m467 m797.7 m

Total Liabilities

323.5 m836.1 m941.8 m1.2 b

Retained Earnings

164.4 m275.7 m158.8 m(26.3 m)

Total Equity

(43.4 m)(325 m)(216.1 m)(228.5 m)

Financial Leverage

-6.5 x-1.6 x-3.4 x-4.1 x
GBPFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

520.2 m301 m247.8 m315.2 m

Cash From Financing Activities

(530 m)(61.6 m)(111.5 m)(113.8 m)

Income Taxes Paid

(135.5 m)(108.1 m)(44.1 m)(48.8 m)
Y, 2016

Financial Leverage

-4.1 x

Indivior Operating Metrics

Indivior's Clinical Programs was reported to be 12 in FY, 2016
FY, 2016

Phase III Trials


Clinical Programs


Phase I Trials


Phase II Trials


Indivior Market Value History

Indivior News and Updates

Indivior Company Life and Culture

You may also be interested in